#Humira Market Report

[mitalipingale]

https://theomnibuzz.com/humira-market-size-analysis-and-forecast-2031/

The Humira Market in 2023 is US$ 8.7 billion, and is expected to reach US$ 13.18 billion by 2031 at a CAGR of 5.33%.

[mohammed-niraz]

Help Rebuild Lives in Gaza: Support Families in Crisis

These Funds will help 4 families from Gaza stay alive campaign link: https://gofund.me/80d75b89

I am Mohammed, and I urgently need your help to support four families in Gaza who are facing life-altering challenges due to ongoing conflict. Your compassionate contributions will provide essential medical care, daily necessities, and a chance for these families to rebuild their lives.

Mohammed Nasser: A Story of Resilience in Gaza

I am Mohammed Nasser, currently displaced in Zawaida, living in a small tent with my family. Before the violence escalated on October 7, I worked as a digital marketer, which allowed me to provide for my loved ones. Unfortunately, I lost my laptop—my primary source of income—due to the conflict, leaving my family vulnerable.

These images reflect my significant losses, showing the many job opportunities I’ve missed due to the conflict. Each one was a chance for growth and crucial support for my family, highlighting our urgent need for assistance in this challenging time.

My Mother And Father

My elderly parents urgently need medical care. My mother suffers from rheumatoid arthritis and requires Humira injections, along with daily medications for hypertension. My father also struggles with hypertension and needs continuous monitoring. Your support can help restore stability and provide the medical resources my family desperately needs.

Humira Injection

The Medical Report of My Mother The Medical Report of My Mother

Marwan Nasser: A Lawyer’s Fight for Family Safety

My brother, Marwan Nasser, is a dedicated lawyer whose life was turned upside down when his law firm was destroyed. Together with his wife, Nisreen, and their two young children, Niraz (4) and Lilia (1), Marwan is striving to protect his family from the psychological effects of the ongoing conflict. The sounds of war have left Niraz anxious and fearful. Marwan seeks help to ensure his family’s safety and well-being during this tumultuous time.

Your contributions will help Marwan create a secure environment for his children, allowing them to thrive despite the chaos around them.

Loay: A Determined Student’s Journey

Loay, my brother, is a bright student who dreams of completing his education despite the hardships of living in a conflict zone. His commitment to learning is unwavering, but he faces significant challenges in accessing resources. With your support, Loay can continue his studies and work towards a brighter future for himself and his family.

Diana Anan: A Mother’s Hope for a Safe Future

Diana Anan, my sister, is a devoted mother of two daughters, Jenan (8) and Lelyan (7). After losing their home and several family members to airstrikes, Diana strives to create a safe environment for her children. The trauma of war weighs heavily on them, and her heartfelt wish is to give her daughters a hopeful future free from fear.

Madleen Hamadeh: A Mother’s Heartfelt Plea for Help

Madleen Hamadeh, also a sister and mother to three young children—Yousef (6), Amir (5), and Maram (1.5)—has seen her family’s joy eroded by war. Their home was bombed, and the emotional toll on her children is profound. Madleen seeks help to provide her kids with basic needs like food and clean water, aiming to restore some normalcy to their lives.

How Your Donations Will Help Families in Gaza

Your generous contributions will directly support these families in the following ways:

● Medical Care for Elderly Parents:

○ Humira Injections: $2,400

○ Knee Treatment: $4,000

○ Blood Pressure Medications: $500

○ Ongoing Treatments: $500

● Daily Living Expenses for Families in Gaza:

○ Clean Water: $2,520/year

○ Healthy Food: $24,000/year

○ Clothes: $7500/year

● Emergency Expenses:

○ Transportation and urgent needs: $8,000

● Educational Needs for Children:

○ Laptops and school supplies: $4,000

● Professional Restart Costs:

○ Laptop for Work: $1,000

○ Office Equipment: $3,000

○ Solar energy and batteries: $2500

Total Needed: $58,000

"Every donation is a lifeline, a chance to rewrite the future for those in need. Your support can bring hope and healing to families facing unimaginable challenges. Join us in making a difference—share this campaign within your community and let’s transform lives together. Together, we can turn compassion into action and create a brighter tomorrow for all."

[help-gazans-family]

Help Rebuild Lives in Gaza: Support Families in Crisis

These Funds will help 4 families from Gaza stay alive https://gofund.me/80d75b89

I am Mohammed, and I urgently need your help to support four families in Gaza who are facing life-altering challenges due to ongoing conflict. Your compassionate contributions will provide essential medical care, daily necessities, and a chance for these families to rebuild their lives.

Mohammed Nasser: A Story of Resilience in Gaza

I am Mohammed Nasser, currently displaced in Zawaida, living in a small tent with my family. Before the violence escalated on October 7, I worked as a digital marketer, which allowed me to provide for my loved ones. Unfortunately, I lost my laptop—my primary source of income—due to the conflict, leaving my family vulnerable.

These images reflect my significant losses, showing the many job opportunities I’ve missed due to the conflict. Each one was a chance for growth and crucial support for my family, highlighting our urgent need for assistance in this challenging time.

My Mother And Father

My elderly parents urgently need medical care. My mother suffers from rheumatoid arthritis and requires Humira injections, along with daily medications for hypertension. My father also struggles with hypertension and needs continuous monitoring. Your support can help restore stability and provide the medical resources my family desperately needs.

Humira Injection

The Medical Report of My Mother The Medical Report of My Mother

The M

Marwan Nasser: A Lawyer’s Fight for Family Safety

My brother, Marwan Nasser, is a dedicated lawyer whose life was turned upside down when his law firm was destroyed. Together with his wife, Nisreen, and their two young children, Niraz (4) and Lilia (1), Marwan is striving to protect his family from the psychological effects of the ongoing conflict. The sounds of war have left Niraz anxious and fearful. Marwan seeks help to ensure his family’s safety and well-being during this tumultuous time.

Your contributions will help Marwan create a secure environment for his children, allowing them to thrive despite the chaos around them.

Loay: A Determined Student’s Journey

Loay, my brother, is a bright student who dreams of completing his education despite the hardships of living in a conflict zone. His commitment to learning is unwavering, but he faces significant challenges in accessing resources. With your support, Loay can continue his studies and work towards a brighter future for himself and his family.

Diana Anan: A Mother’s Hope for a Safe Future

Diana Anan, my sister, is a devoted mother of two daughters, Jenan (8) and Lelyan (7). After losing their home and several family members to airstrikes, Diana strives to create a safe environment for her children. The trauma of war weighs heavily on them, and her heartfelt wish is to give her daughters a hopeful future free from fear.

Madleen Hamadeh: A Mother’s Heartfelt Plea for Help

Madleen Hamadeh, also a sister and mother to three young children—Yousef (6), Amir (5), and Maram (1.5)—has seen her family’s joy eroded by war. Their home was bombed, and the emotional toll on her children is profound. Madleen seeks help to provide her kids with basic needs like food and clean water, aiming to restore some normalcy to their lives.

How Your Donations Will Help Families in Gaza

Your generous contributions will directly support these families in the following ways:

● Medical Care for Elderly Parents:

○ Humira Injections: $2,400

○ Knee Treatment: $4,000

○ Blood Pressure Medications: $500

○ Ongoing Treatments: $500

● Daily Living Expenses for Families in Gaza:

○ Clean Water: $2,520/year

○ Healthy Food: $24,000/year

○ Clothes: $7500/year

● Emergency Expenses:

○ Transportation and urgent needs: $8,000

● Educational Needs for Children:

○ Laptops and school supplies: $4,000

● Professional Restart Costs:

○ Laptop for Work: $1,000

○ Office Equipment: $3,000

○ Solar energy and batteries: $2500

Total Needed: $58,000

"Every donation is a lifeline, a chance to rewrite the future for those in need. Your support can bring hope and healing to families facing unimaginable challenges. Join us in making a difference—share this campaign within your community and let’s transform lives together. Together, we can turn compassion into action and create a brighter tomorrow for all." https://gofund.me/80d75b89

[trendingrepots]

Adalimumab Market - Forecast(2024 - 2030)

Adalimumab Market Overview

Adalimumab Market Size is forecast to reach $3245.8 Million by 2030, at a CAGR of 6.20% during forecast period 2024-2030. Adalimumab is a monoclonal antibody and disease-modifying antirheumatic medication that acts by inactivating tumor necrosis factor-alpha. It is marketed under the brand names Humira and Exemptia, among others. The original adalimumab drug is sold under the brand name Humira. New versions of adalimumab are known as adalimumab biosimilars. Biosimilars are similar versions of original biological medicines. Adalimumab is a drug used to treat rheumatoid arthritis and ankylosing spondylitis which affects the musculoskeletal system, Crohn’s disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and other diseases. It was first introduced in the United States by Abbvie and was approved by the FDA in 2002. It is used to alleviate inflammation by acting on the immune system. The growing prevalence of arthritis and skin disorders, adoption of a sedentary lifestyle, and growing obese population are some of the factors driving the Adalimumab Market growth during the forecast period 2024-2030.

 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞

Report Coverage

The report: “Adalimumab Market Forecast (2024-2030)", by Industry ARC covers an in-depth analysis of the following segments of the Adalimumab Market.

By Disease- Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others. By Type- Adalimumab, Adalimumab Biosimilar. By End-Users- Hospitals, Specialty Clinics, and Others. By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of psoriasis arthritis, highly informed people knowing the benefits of adalimumab, and high healthcare expenditure. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to increasing prevalence of Crohn's disease and ulcerative colitis., demand for better healthcare facilities as well a boost in the investments done by government and private companies in pharma industry. The proliferation of Rheumatoid arthritis is predicted to augment the market growth during the forecast period of 2022-2027.

The growing prevalence of arthritis and skin disorders is estimated to drive the market growth of the Adalimumab Market. High cost as well as lack side effects of adalimumab poses threat to the market growth.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Adalimumab Market Report.

[harshnews]

Psoriasis Treatment Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Global Psoriasis Treatment Market - Industry Trends and Forecast to 2029

Global Psoriasis Treatment Market, By Drug Class (Corticosteroids, TNF Inhibitors, Interleukins, Others), Type (Plaque Psoriasis, Psoriatic Arthritis, Others), Route of Administration (Oral, Parenteral, Topical), Application (Topical Therapeutic Drugs, Systemic Therapeutic Drugs, Combinations), End User (Hospital Pharmacy, Clinics, Retail Pharmacies, Online Sales), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

**Segments**

- **By Drug Class**: The psoriasis treatment market can be segmented based on drug class, which includes biologics, systemic therapy, topical therapy, and others. Biologics are becoming increasingly popular due to their targeted approach in treating psoriasis at a molecular level. Systemic therapy involves oral or injectable medications that affect the entire immune system to manage psoriasis symptoms. Topical therapies include creams, ointments, and lotions applied directly to the skin to alleviate mild to moderate symptoms.

- **By Route of Administration**: Another important segmentation in the psoriasis treatment market is based on the route of administration. This includes oral, injectable, and topical routes. Oral medications are often prescribed for systemic treatment, while injectable biologics are administered via subcutaneous or intravenous routes. Topical treatments are primarily used for localized psoriasis management.

- **By Distribution Channel**: The distribution channel segment categorizes the market based on where patients can access psoriasis treatments. This includes hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. Hospital pharmacies are common for inpatient treatments, while retail pharmacies cater to outpatient prescriptions. Online pharmacies are gaining popularity due to convenience, and specialty clinics focus on dermatological care for psoriasis patients.

**Market Players**

- **AbbVie Inc.**: AbbVie is a leading player in the psoriasis treatment market, offering biologics like Humira (adalimumab) for psoriasis management.

- **Johnson & Johnson Services, Inc.**: Johnson & Johnson is known for its systemic therapy options for psoriasis, such as Stelara (ustekinumab) and Tremfya (guselkumab).

- **Novartis AG**: Novartis is a key player with a strong portfolio of psoriasis treatments, including Cosentyx (secukinumab) and Methotrexate.

- **Amgen Inc.**: Amgen has a range of biThe psoriasis treatment market is a dynamic and evolving sector with several key players driving innovation and advancements in treatment options for patients. AbbVie Inc. is a prominent player in the market, offering biologics like Humira (adalimumab) that have demonstrated efficacy in managing psoriasis symptoms. Biologics have gained significant traction in the market due to their targeted approach at the molecular level, offering a more personalized and effective treatment option for patients. Johnson & Johnson Services, Inc. is another major player known for its systemic therapy options such as Stelara (ustekinumab) and Tremfya (guselkumab), which have shown promise in managing moderate to severe psoriasis.

Novartis AG, with its strong portfolio of psoriasis treatments including Cosentyx (secukinumab) and Methotrexate, has been instrumental in improving outcomes for patients with psoriasis. These treatments target specific pathways involved in the development of psoriasis, providing patients with more targeted and effective treatment options. Amgen Inc., with its range of biologics like Enbrel (etanercept), has also made significant contributions to the market by providing new insights and advancements in psoriasis treatment.

The market for psoriasis treatments is witnessing a shift towards more personalized and targeted therapies, driven by advancements in biologics and systemic therapies. Biologics, in particular, have revolutionized the treatment landscape for psoriasis by targeting specific molecules involved in the inflammatory response associated with the condition. These targeted therapies have shown significant efficacy in managing psoriasis symptoms and improving quality of life for patients.

The distribution channels for psoriasis treatments play a crucial role in ensuring access to these therapies for patients. Hospital pharmacies are essential for inpatient treatments, while retail pharmacies cater to outpatient prescriptions, providing convenient access to medications for patients. Online pharmacies have also emerged as a popular choice for patients seeking convenience and accessibility in obtaining their psoriasis treatments. Specialty clinics focusing on dermatological**Global Psoriasis Treatment Market**

- **Segments** - **By Drug Class**: The psoriasis treatment market encompasses a variety of drug classes, including corticosteroids, TNF inhibitors, interleukins, and others. Corticosteroids are commonly used for their anti-inflammatory properties, while TNF inhibitors and interleukins target specific pathways in the immune system to manage psoriasis symptoms. Other drug classes offer alternative mechanisms of action for psoriasis treatment. - **By Type**: The types of psoriasis targeted in the market include plaque psoriasis, psoriatic arthritis, and other less common forms of the condition. Different types of psoriasis may require specific treatment approaches tailored to the patient's symptoms and disease progression. - **By Route of Administration**: Psoriasis treatments can be administered through various routes, such as oral, parenteral, and topical. Oral medications are often used for systemic treatment, while parenteral routes involve injections for targeted therapy. Topical treatments are applied directly to the skin for localized symptom management. - **By Application**: The applications of psoriasis treatment include topical therapeutic drugs, systemic therapeutic drugs, and combination therapies. These different applications offer a range of options for patients and healthcare providers to address the varying severity of psoriasis symptoms. - **By End User**: The end users in the psoriasis treatment market span hospital pharmacies, clinics, retail pharmacies, and online sales. Each end user plays a crucial role in ensuring access to psoriasis

The Psoriasis Treatment Market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance.

Major Points Covered in TOC:

Psoriasis Treatment Market Overview: It incorporates six sections, research scope, significant makers covered, market fragments by type, Psoriasis Treatment Market portions by application, study goals, and years considered.

Psoriasis Treatment Market Landscape: Here, the opposition in the Worldwide Psoriasis Treatment Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, obtaining, and portions of the overall industry of top organizations.

Psoriasis Treatment Profiles of Manufacturers: Here, driving players of the worldwide Psoriasis Treatment Market are considered dependent on deals region, key items, net edge, income, cost, and creation.

Psoriasis Treatment Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income, creation, portion of the overall industry, CAGR, and market size by locale. Here, the worldwide Psoriasis Treatment Market is profoundly examined based on areas and nations like North America, Europe, China, India, Japan, and the MEA.

Psoriasis Treatment Application or End User: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide Psoriasis Treatment Market.

Psoriasis Treatment Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge, and creation and creation esteem estimate by type.

Keyword: Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

What to Expect from the Report, a 7-Pointer Guide

The Psoriasis Treatment Market report dives into the holistic Strategy and Innovation for this market ecosystem

The Psoriasis Treatment Market report keenly isolates and upholds notable prominent market drivers and barriers

The Psoriasis Treatment Market report sets clarity in identifying technological standardization as well as the regulatory

framework, besides significantly assessing various implementation models besides evaluation of numerous use cases

The Psoriasis Treatment Market report is also a rich repository of crucial information across the industry, highlighting details on novel investments as well as stakeholders and relevant contributors and market participants.

A through market analytical survey and forecast references through the forecast tenure, encapsulating details on historical developments, concurrent events as well as future growth probability

Browse Trending Reports:

Calcium Glycinate Market Retinal Biologics Market Facial Fat Transfer Market Angio Suites Diagnostic Imaging Market Adoption Of Benelux Power Tools Market De Quervains Tenosynovitis Treatment Market Biodetectors And Accessories Market Colposcope Market Sports Medicine Market Automotive Adhesives Market Infrared Imaging Market Vapour Deposition Market Professional Diagnostics Market Ct Scanner Market Programmable Application Specific Integrated Circuit Asic Market Hospital Operating Room Or Products And Solutions Market Castor Oil Market Zika Virus Infection Drug Market Toluene Diisocynate Market Antibiotic Resistance Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[newsmarketreports]

Celltrion Inc.: Financial Performance Overview

Celltrion Financials is a South Korean biopharmaceutical company, known for its leadership in developing biosimilars and biologics. The company focuses on producing affordable, high-quality biologic drugs for the treatment of autoimmune diseases, cancer, and other chronic illnesses. Below is a summary of its financial performance based on available information.

1. Revenue Growth

Strong Sales of Biosimilars: Celltrion has seen consistent growth in revenue, primarily driven by the global sales of its biosimilars such as Remsima (a biosimilar to Remicade), Truxima (a biosimilar to Rituxan), and Herzuma (a biosimilar to Herceptin). These products are approved in multiple regions, including the U.S., Europe, and Asia, contributing significantly to the company's topline.

Year-over-Year Revenue Increase: Celltrion has experienced strong revenue growth in recent years, often reporting double-digit percentage increases in annual sales. This growth is fueled by increasing market adoption of biosimilars and new product launches.

2. Profit Margins

High Gross Margins: Celltrion benefits from relatively high gross margins due to the cost-efficiency of its manufacturing processes and the lower R&D costs associated with biosimilars compared to original biologic drugs. Its state-of-the-art manufacturing facilities in South Korea contribute to economies of scale.

Operating Income: The company’s operating income has also been growing steadily, supported by both rising sales and cost-control measures. Celltrion’s ability to scale production efficiently while maintaining competitive pricing has been a key driver of profitability.

3. R&D Expenditure

Investments in Pipeline Development: Celltrion continues to invest heavily in research and development (R&D), focusing on expanding its biosimilar pipeline and developing new biologic treatments. This includes the development of biosimilars for blockbuster drugs as well as innovative biologics for cancer and autoimmune diseases.

R&D as a Percentage of Revenue: Celltrion’s R&D expenditure represents a significant portion of its annual revenue, reflecting its long-term commitment to innovation and expanding its product portfolio. The company is focused on developing next-generation biologics and biosimilars, which will drive future growth.

4. Global Market Expansion

International Sales Contribution: A significant portion of Celltrion’s revenue comes from its international operations, particularly in Europe and the U.S., where biosimilars have gained widespread acceptance. The company has been actively pursuing regulatory approvals in various regions, which has contributed to its robust revenue growth.

Partnerships and Alliances: Celltrion has established strategic partnerships with global pharmaceutical companies for the marketing and distribution of its biosimilar products. These partnerships have played a key role in driving global sales and market penetration.

5. Impact of COVID-19

COVID-19 Treatment Development: During the COVID-19 pandemic, Celltrion played an active role in developing treatments for the virus. The company developed Regkirona (CT-P59), a monoclonal antibody treatment for COVID-19. This has contributed to additional revenue streams and positioned the company as a key player in pandemic response efforts.

Increased Demand for Biologics: The pandemic heightened the global demand for biologics, which benefited Celltrion’s biosimilar portfolio as healthcare systems sought cost-effective treatments for chronic diseases amidst budget constraints.

6. Outlook and Future Growth

Biosimilar Pipeline: Celltrion’s future growth is expected to be driven by the launch of new biosimilars currently in its pipeline. These include biosimilars for drugs like Humira (adalimumab), which has been one of the world’s top-selling drugs, and other monoclonal antibodies.

Innovative Biologics: Beyond biosimilars, Celltrion is working on developing innovative biologic treatments that could further bolster its revenue streams and market position.

Expansion into New Markets: Celltrion continues to focus on expanding into new international markets, particularly in emerging regions where demand for affordable biologic treatments is increasing.

Conclusion

Celltrion Inc. has demonstrated strong financial performance, supported by its leadership in the biosimilar market, efficient manufacturing capabilities, and strategic international partnerships. With a robust product pipeline, continued R&D investments, and a focus on global market expansion, Celltrion is well-positioned for future growth in the biopharmaceutical industry.

[shubhampawrainfinium]

Psoriasis Treatment Unveiled: The Latest in Therapeutic Advances

According to the report, the global psoriasis therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 9% over the forecast period from 2022 to 2028. The market generated revenue of approximately USD 24 billion in 2022 and is expected to reach nearly USD 44 billion by 2028.

Understanding Psoriasis Therapeutics

Psoriasis is a chronic autoimmune disease that results in the rapid buildup of skin cells, causing scaling and inflammation. Psoriasis therapeutics include a range of treatments such as topical therapies, phototherapy, and systemic treatments, including biologics and small-molecule drugs, aimed at reducing symptoms and managing flare-ups.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/825

Market Dynamics and Growth Drivers

The significant growth of the global psoriasis therapeutics market is driven by several factors:

Rising Prevalence of Psoriasis: The global incidence of psoriasis is increasing, leading to a growing patient pool that requires long-term therapeutic solutions. With millions affected worldwide, demand for effective treatments is on the rise.

Advancements in Biologics: Innovations in biologic drugs have transformed the treatment landscape for psoriasis. Biologics, which target specific components of the immune system, have proven highly effective in treating moderate to severe cases, contributing to the market's growth.

Increased Awareness and Diagnosis: Greater awareness of psoriasis and advancements in diagnostic tools are leading to earlier and more accurate diagnoses, ensuring patients receive timely treatment, thereby boosting demand for therapeutics.

Improved Treatment Accessibility: Growing accessibility to advanced treatments, particularly in emerging markets, is also propelling market growth. Governments and healthcare providers are making strides to ensure affordable treatments for patients suffering from psoriasis.

Regional Analysis

North America: North America, particularly the U.S., holds the largest share of the global psoriasis therapeutics market. The region's robust healthcare infrastructure, high psoriasis incidence, and access to advanced biologic treatments drive its market dominance.

Europe: Europe is also a major market for psoriasis therapeutics, with countries like Germany, France, and the U.K. leading the region. Increased healthcare spending and a rising number of biologic approvals are key contributors to the market's growth.

Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth during the forecast period. Growing awareness, improved healthcare infrastructure, and increasing government initiatives to manage chronic diseases are fueling the demand for psoriasis therapies.

Latin America and Middle East & Africa: These regions are slowly adopting psoriasis treatments due to improving healthcare systems and increased awareness. However, the market here is still in the early stages of development.

Competitive Landscape

The psoriasis therapeutics market is highly competitive, with key players focusing on research and development to introduce more effective and targeted therapies:

AbbVie Inc.: Known for its blockbuster drug Humira, AbbVie is a major player in the psoriasis biologics segment. The company's strong R&D pipeline positions it for continued growth in this market.

Novartis AG: Novartis has made significant strides with its biologic Cosentyx, which has been highly effective in treating moderate to severe psoriasis cases.

Eli Lilly and Company: Eli Lilly's Taltz, another biologic therapy, is making waves in the market with its efficacy and fast-acting results for psoriasis patients.

Johnson & Johnson (Janssen): The company offers the biologic treatment Stelara, which has become a popular option for patients with moderate to severe psoriasis.

Amgen Inc.: Amgen's focus on biologics, particularly Enbrel, has made it a major contender in the psoriasis therapeutics market.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-psoriasis-therapeutics-market

Challenges and Opportunities

While the market is experiencing significant growth, it also faces several challenges:

High Treatment Costs: Biologic therapies, while highly effective, are expensive, limiting access for patients in low- and middle-income regions. Developing cost-effective treatments will be key to expanding the market's reach.

Side Effects and Patient Adherence: Some psoriasis treatments come with side effects, leading to patient adherence issues. Improving the safety profile of these therapies is essential for long-term growth.

Regulatory Approvals: Gaining regulatory approval for new treatments, particularly in regions with strict regulations, can be a hurdle for companies looking to launch innovative therapies.

Despite these challenges, the market presents significant opportunities. The growing trend toward personalized medicine, which tailors treatments to individual patient profiles, is expected to create new avenues for growth. Additionally, ongoing research into novel biologics and small molecules promises to further enhance treatment options for psoriasis patients.

Conclusion

The global psoriasis therapeutics market is poised for robust growth, with projected revenue of nearly USD 44 billion by 2028. With rising disease prevalence, advancements in biologic therapies, and expanding treatment access, the market presents vast opportunities for innovation and investment. As the focus on improving patient outcomes and developing cost-effective solutions increases, the psoriasis therapeutics market is set to witness significant advancements over the forecast period.

[euro-industry-org]

Pharmaceutical industry forecasts to 2026

One of the major issues currently plaguing the pharmaceutical sector relates to clinical trials. Since the spread of the coronavirus, hundreds of trials have been suspended and the issuing of opinions on those that have been conducted is delayed. This problem means that the longer this situation continues, the more likely it is that regulatory decision-making will be slowed down. This, of course, could affect patient access to new medical solutions. And from a macroeconomic perspective, the loss of jobs and productivity indicates that a global economic downturn is coming. If this proves true, governments and patients will have less and less money to spend on healthcare. In this context, investors seem to have sidelined the economic risks of a pandemic, hoping they will be offset by the potential of new treatments for the disease.

Market share growth

The only companies that have reported projected market share gains by 2026 are AstraZeneca, BMS and AbbVie. In the case of BMS, the deal that has contributed most to this growth is the acquisition of Celgene. For AbbVie, the acquisition of Allergan has had a very positive impact, being a strategically favourable move to diversify its drug portfolio, also in view of the impending loss of exclusivity for Humira in 2023.

AstraZeneca's market share is expected to grow steadily; mainly driven by sales of drugs such as Tagrisso, Lynparza and Imfinzi, which continue to be the UK company's growth drivers. Takeda will remain on the sidelines in the ranking of the top ten best-selling prescription drugs for 2026. Despite the acquisition of Shire in 2019 and its contribution to the company's revenue growth, there are downsides. One of the most notable is the patent expiration of the Advate drug in 2019, resulting in a drop in sales of about a billion dollars. Overall, the top ten pharmaceutical companies will lose 6.2% of total market share. And the main impact of this phenomenon will be Pfizer.

The rise of biotechnology

It is worth noting that biotechnology is set to change direction in the coming years. By 2026, biotech drugs are expected to occupy a major share of the top 100 drugs, accounting for 55% of the total, up 16% from 2012. In this context, Roche will remain the largest company in biologic drugs. A detailed analysis of Roche's data shows that despite losing 5.8% of market share due to the loss of biologics patents, the company is still the largest biologics manufacturer in the world. These include Avastin, Herceptin and Rituxan, which account for the company's largest sales. According to another forecast in the report, Amgen will drop two positions due to the loss of market share of its Enbrel (autoimmune diseases) drug compared to similar drugs from competitors.

Following it, Novo Nordisk will move to the third position, boosted by strong sales growth of Ozempic and Ribelsus (diabetes drugs), which will have sales of about $15 billion by 2026. The paper also predicts that AbbVie will drop out of the top ten leaders in this field. This will occur as a result of the loss of the Humira patent in the US by 2023. Novartis will join the top ten in this segment due to sales growth of Cosentyx and Entresto (psoriasis and heart failure drugs respectively); also among the drugs driving the company's growth will be the launches of Arzerra (chronic lymphocytic leukaemia) and Inclisiran (an experimental molecule being studied for the treatment of atherosclerotic cardiovascular disease).

Diversified research

The EvaluatePharma report also looks at the most promising R&D projects up to 2026. The list of initiatives is diversified across several therapeutic areas, with large corporations actively participating, but there is also room for mid-cap companies to sneak into the ranking. In first place is tirzepatide, Eli Lilly's diabetes and obesity drug. It moved up in the rankings thanks to Eli Lilly's focus on it, comparing it in trials to its drug Trulicity, which brings the company big sales. Novartis is in second place thanks to Inclisiran, a molecule being investigated for the treatment of atherosclerotic cardiovascular disease. Inclisiran became part of Novartis Group's armoury through its acquisition of The Medicines Company earlier this year. Approval of the therapy is expected in the second half of this year, and the drug is expected to compete directly with Repatha (Amgen) in the atherosclerotic disease drug line-up.

There are also high hopes for Biogen's Alzheimer's disease drug aducanumab. The drug, which targets the beta-amyloid protein, was due to be submitted to the FDA in early 2020; delays caused by the current situation could make investors nervous, given that it could be the first new drug to treat this type of dementia in 15 years. In the area of autoimmune diseases, Bristol-Myers Squibb has BMS-986165, an investigational tyrosine kinase inhibitor for the treatment of psoriasis. The drug is expected to show good results and help BMS recover sales in psoriasis following the sale of its Otezla drug following its merger with Celgene.

Diverse specialities

GlaxoSmithKline's multiple myeloma drug belantamab mafodotin made the ranking. Roche also made the top 10 due to promising research projects with its drug for the treatment of spinal muscular atrophy, rizdiplam. The therapy has received a priority review from the FDA, but the Swiss company is awaiting a final decision due by the end of August.

Among the smaller companies' projects, four made it into the top 10. In first place is argenx with its immunosuppressant efgartimod, which has had good results in trials on patients with generalised myasthenia gravis. Then there is the collaboration between Vir Biotechnology and Alnylam to develop ALN-HBV02, an RNAi therapy for the treatment of chronic hepatitis B infections. Also in this group of mid-cap companies is Iovance Biotherapeutics with its cell therapy that has received FDA fast track status for the treatment of advanced melanoma. Rounding out this group is Allakos with its esophagitis and gastritis drug currently in Phase 3 clinical trials.

Product ranking

While not grouping drugs by speciality, the consultancy also ranked the ten drugs expected to be the top-selling drugs by 2026. As mentioned above, the list will be topped by Keytruda, an anti-PD-1 immunotherapy drug. Second place will also go to immunotherapy drugs, in this case Opdivo, whose mechanism of action is similar to Keytruda. In third place is Eliquis (apixaban), an anticoagulant used to prevent venous thromboembolism and stroke in patients suffering from atrial fibrillation. Bictarvi (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate), an antiviral drug from Gilead Sciences used in patients with HIV, ranked fourth.

In the middle of the table, in fifth place, would be Imbruvica (ibrutinib), a drug developed by AbbVie and Janssen, a Bruton's tyrosine kinase inhibitor used to treat patients with mantle cell lymphoma. Oncology is also in sixth and seventh places with Pfizer's Ibrance (palbociclib) for the treatment of certain breast cancers and Tagrisso (osimertinib mesylate), an EGFR inhibitor for the treatment of non-small cell lung cancer.

The last three positions in the table are occupied by drugs from different fields. In eighth place is Sanofi's Dupixent (dupilumab), an interleukin 4 and 13 inhibitor for patients with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis. Ninth place went to Vertex Pharmaceuticals' Trikafta (elexacaftor, ivacaftor, tezacaftor), an advanced therapy for the treatment of cystic fibrosis. Finally, closing the table in tenth place is Ozempic (semaglutide) from NovoNordisk Pharmaceuticals, used as a diabetic drug - which can be combined with other therapies - to prevent the development of cardiovascular disease in these patients.

[omkarmeds]

Everything You Must Know About Colistin injection

Rheumatoid arthritis, abbreviated as RA, is a type of autoimmune disease that leads to inflammation and stiffness of the joints. If neglected, it results in deformity of the joint, pain and loss of functional ability. Adalimumab is a TNF inhibitor brand-named Humira, specifically used in patients with moderate to severe rheumatoid arthritis when other drugs have provided inadequate relief. TNF and inflammation How the drug works The drug belongs to a general class of drugs referred to as biological agents or biologics, and it works by preventing the action of a protein referred to as TNF, which provokes inflammation.

Are you looking for Adalimumab injection? Adalimumab is a self-administered drug that is given through subcutaneous injections and the dosage administered is usually once in one or two weeks. In their case, it usually takes several weeks to observe the RA symptoms start improving. Some of them include reactions at the site of injection, increasing susceptibility to infections, and, in a very limited number of patients, some nervous disorders and specific types of cancer. Nevertheless, research has shown that adalimumab can effectively treat RA by inducing remission and preventing further joint deterioration if administered according to the prescription of a healthcare provider.

Regarding antibiotics, the world is facing one of the major health risks in the form of resistance. Most of the ordinary bacteria have developed a resistance to more than one type of antibiotics, as such, infections have become more difficult to handle. Among all the resistant bacterium, one is Acinetobacter baumannii, which leads to pneumonia, bloodstream infection, and surgical site infection in healthcare associated settings.

Acinetobacter is one of the most problematic highly resistant bacteria which has few treatment options, and colistin is one of the older antibiotics that are now considered as the last resort. It is given through an injection and is more toxic than the current antibiotics on the market and has been known to cause effects such as kidney damage and neuropathy. However, some studies have reported that intravenous Colistin injection can serve as the last resort for treating extremely antibiotic-resistant organisms.

The implications of safety and efficacy, the need to adhere to antibiotic stewardship, and the fact that antibiotics are developed at a slow pace also poses challenges to clinicians. This is true despite the fact that medications such as adalimumab, a biological agent, have significantly transformed the management of autoimmune diseases if appropriately applied.

[spookysaladchaos]

Antibody Drugs, Global Market Size Forecast, Top 20 Players Rank and Market Share

Antibody Drugs Market Summary

Antibody drugs refer to a type of drugs prepared through biotechnology, the main component of which is antibody molecules. Antibodies are proteins produced by the immune system that recognize and bind to specific molecules (antigens), thereby modulating the immune response or directly inhibiting the activity of disease-related molecules. Antibody drugs treat diseases by simulating or enhancing the body's own immune system and are highly specific and biologically active.

According to the new market research report "Global Antibody Drugs Market Report 2023-2029", published by QYResearch, the global Antibody Drugs market size is projected to grow from USD 232.8 billion in 2023 to USD 319.7 billion by 2029, at a CAGR of 5.4% during the forecast period.

Figure.   Global Antibody Drugs Market Size (US$ Million), 2018-2029

Above data is based on report from QYResearch: Global Antibody Drugs Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch.

Market Drivers:

Technological progress: The continuous development of biotechnology has made the development and production of antibody drugs more efficient and precise.

Growing demand: As the population ages and chronic diseases increase, the need for safer and more effective medicines to treat them continues to increase.

Breakthroughs in antibody engineering technology: The emergence of new antibody engineering technologies, such as monoclonal antibody technology, chimeric antibody technology, etc., provides more possibilities for the design and optimization of antibody drugs.

Restraint:

High cost: The development and production costs of antibody drugs are often high, making them expensive and limiting patient access.

Immunogenicity: Since antibody drugs are exogenous proteins, they may trigger an immune response in patients, leading to treatment failure or adverse reactions.

Complexity: The production process of antibody drugs is complex, including cloning, expression, purification and other links, which increases the difficulty of research and development and production.

Opportunity:

Application of new technologies: For example, the development of gene editing technology provides new possibilities for the design and production of antibody drugs.

Personalized treatment: With the advancement of medical technology, personalized treatment is receiving more and more attention. As a highly specific treatment method, antibody drugs will have broader application prospects.

Application of polyclonal antibodies: Polyclonal antibody therapy can target multiple targets at the same time and has wider therapeutic adaptability, which is an important direction for future development.

Figure.   Global Antibody Drugs Top 20 Players Ranking and Market Share (Ranking is based on the revenue of 2022, continually updated)

Above data is based on report from QYResearch: Global Antibody Drugs Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch.

This report profiles key players of Antibody Drugs such as Keytruda、Humira、Dupixent、Stelara、Opdivo.

In 2022, the global top five Antibody Drugs players account for 32% of market share in terms of revenue. Above figure shows the key players ranked by revenue in Antibody Drugs.

About The Authors

Author: Wang Ting

Main areas: Semiconductors and consumer electronics

Email: wangting@qyresearch.com

Contact number: 17877785868

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

[alicesara611]

Forecasting Success: Examining the Humira Market's Trajectory Over By 2023 to 2030

The global humira market is expected to reach US$ 3871.4 million by 2030, at a CAGR of 25.9%. The market is driven by the increasing prevalence of inflammatory diseases, the aging population, and the rising demand for biologics, driven by factors such as an aging population, rising prevalence of chronic inflammatory diseases, and advancements in medical technology. However, the introduction of biosimilars, which are highly similar to Humira in terms of structure and function, is expected to disrupt the market dynamics.

In the realm of pharmaceuticals, Humira, a tumor necrosis factor (TNF) blocker, stands as a towering figure, having revolutionized the treatment of inflammatory conditions. Its efficacy and broad spectrum of applications have propelled it to the forefront of the healthcare industry, generating substantial revenue and garnering significant attention. However, as Humira's patent protection wanes, the market landscape is poised for a significant transformation, with the emergence of biosimilars and the potential for increased competition.

Get your Sample Report with Latest Market Information! https://absolutemarketresearch.com/Global-Humira-Market/1269/request-sample

The Humira market is poised for a period of significant change and evolution in the coming years. The emergence of biosimilars will undoubtedly reshape the market landscape, introducing new players and intensifying competition. While Humira is expected to maintain a strong position in the market, biosimilars are poised to capture a growing share, offering patients with more affordable treatment options. The Humira market will undoubtedly remain dynamic and evolving, presenting both challenges and opportunities for industry players.

Humira Market: Key Takeaways:

The global Humira market is expected to reach US$ 3871.4 million by 2030, growing at a CAGR of 25.9%.

The increasing prevalence of inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, is driving the growth of the Humira market.

The rising adoption of biosimilars is expected to put pressure on Humira's prices, but it is also expected to expand the market by making Humira more accessible to patients in developing countries.

The Asia-Pacific region is expected to be the fastest-growing market for Humira, driven by the increasing prevalence of inflammatory diseases and the growing adoption of biosimilars.

Humira Market Regional Outlook:

North America is the largest market for Humira, accounting for over 60% of the global market share in 2023.

Europe is the second-largest market for Humira, accounting for over 30% of the global market share in 2023.

The Asia-Pacific region is the fastest-growing market for Humira, due to the increasing prevalence of inflammatory diseases and the growing adoption of biosimilars.

Humira Market Key Players:

AbbVie

Amgen

Boehringer Ingelheim

Cadila Healthcare

Eisai

Torrent Pharmaceuticals

Humira Market Segmentation:

By Indication:

Rheumatoid Arthritis

Psoriatic Arthritis

Crohn's Disease

Ulcerative Colitis

Ankylosing Spondylitis

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

By Type:

Humira Syringe

Humira Pen

By Dosage Strength:

40mg/0.4mlg

80mg/0.8mlg

20mg/0.2mlg

10mg/0.1mlg

By Drug Type:

Branded

Generics

By Route of Administration:

Parenteral

Oral

By Population Type:

Adults

Children

By End User:

Hospital/Clinical Laboratories

Physician Offices

Reference Laboratories

Other End Users

By Distribution Channel:

Direct Tender

Pharmacy

E-commerce

[kenresearch1]

The US Biosimilar market is expected to reach ~USD 96 Bn Industry by 2028

Buy Now

The United States Biosimilar market which currently has a market size of ~USD 9.48 Bn. is expected to grow at a CAGR of ~40% in the next five years and become a ~USD 96 Bn. industry as per the findings of Ken Research.

STORY OUTLINE

Biosimilar drugs tend to be cost effective and this reason is a major factor which contributes highly to the growth of US Biosimilar market.

Rising geriatric population results in an increased demand for Biosimilar drugs which ultimately helps in the growth of US Biosimilar market.

Increasing cases of chronic diseases in the country also raises the demand for Biosimilar drugs thereby accelerating the US Biosimilar market.

Growing partnerships between companies to develop Biosimilar drugs also helps in the growth and expansion of the US Biosimilar market.

A fast growing industry, cost effective nature of Biosimilar, rising cases of chronic diseases, and increase in geriatric population, along with rising strategic partnerships are the various reasons responsible for the growth of US Biosimilar market. This market is anticipated to grow at a CAGR of ~40% in the next five years.

Click to read more about US Biosimilar Market

1.Cost effective nature of Biosimilar drugs: major factor responsible for the growth of US biosimilar market

One of the major reasons behind the significant growth of US Biosimilar market is the cost-effective nature of Biosimilar drugs.

Typically, Biosimilar drugs cost lesser than the generics products due to which they have gained popularity in the healthcare sector. Generally, these drugs cost 30% lesser than the generic or original drugs.

Lucentis is an original drug which is primarily used to treat macular degeneration. This drug is priced at around USD 1200 in the United States.

 Its most common biosimilar is Cimerli which is priced way lesser than Lucentis. It costs around USD 800 in the United States.

Humira is another generic biological which is generally used in the treatment of various autoimmune diseases. This drug is priced at approximately USD 3000. Amjevita is its popular Biosimilar drug which is priced at about USD 1500 in the US which is approximately 50% cheaper than the original drug.

Rituxan is a generic drug which is typically used to treat blood cancer. It is priced at about USD 1000 in the US. Its popular biosimilar drug is Truxima which is priced at about USD 900 in the US.

Herceptin is another expensive generic drug which is mainly used in the treatment of various cancers primarily stomach and breast cancers. The average cost of this generic drug in the US is USD 6800. Ogiviri is its biosimilar drug which is sold at approximately USD 3900 in the US.

Thus, it is evident that biosimilar drugs tend to be more cost effective than the original or generic drugs. Their cost effective nature is a major contributor of the growth of US Biosimilar market.

2.Rising geriatric population: generating the demand for Biosimilar drugs

Click here:- To Download a Sample Report

The geriatric population also has been increasing at a significant rate in the United States. The main reasons behind geriatric population are increase in life expectancy rates and decrease in fertility rates.

There were almost 25 aged people per 100 people in the US in 1980s. The number rose to 32 aged people per 100 people in 1990s. In 2000s, there were 35 aged people per 100 people. 2010 witnessed 40 aged people per 100 people.

 In 2020s, the number reached to 54 aged people per 100 people. This number is further expected to reach 72 aged people per 100 people in 2030s.

As the population rises, aged population becomes vulnerable to many health conditions and they end up requiring many medicines for the treatment of their health conditions.

In the US, approximately 80% of aged people (above 65) have at least one chronic health condition.

The rise in aged population also results in an increased demand for Biosimilar drugs as most of the aged population do not have any strong source of income and thus, they cannot afford generic drugs or original drugs which tend to be really expensive.

Thus, the geriatric population also contribute to the growth of the US Biosimilar market.

3.Increasing cases of chronic diseases: accelerating the US Biosimilar market

The prevalence of chronic health conditions is very high in the United States. A chronic disease is a health condition that prevails for a longer period. Some of the major chronic diseases in the US are cardiovascular diseases, cancer, diabetes, kidney diseases, Alzheimer’s, etc.

In the 2010, there were almost 140 million people living with chronic diseases. In 2015, USA witnessed approximately 150 million people with chronic diseases. This number rose to 155 million people in 2020. Further, this number is anticipated to become 165 million and 170 million people in 2025 and 2030 respectively.

As the prevalence of chronic health conditions rises, their dependence of medicines and drugs also rises. However, not everyone is able to afford original or generic drugs because they tend to be expensive. Thus, that is where the need to develop biosimilar rises.

Moreover, any country would not like to see its people suffer because they cannot afford original drugs. Thus, the countries put emphasis on developing cost effective drugs in the form of Biosimilar drugs.

4.Increasing partnerships between pharmaceutical companies to develop Biosimilar drugs:

Click here:- To Request for Custom Report

Biocon Biologics, a US firm, was involved in the acquisition of Viatris which is a global organization and is concerned with making Biosimilar drugs in the fields of endocrinology, and oncology along with immunology. The main aim of this acquisition was to make their portfolio as well as future Biosimilar drugs pipeline strong.

AbbVie collaborated with Samsung as well as Amgen to develop Biosimilar drugs for Humira which is a generic drug. For this purpose, AbbVie has started to give the license to Samsung as well as Amgen in various countries to produce the Biosimilar.

Teva Pharmaceuticals, which is a pharmaceutical company concerned with development of generic drugs formed a strategic partnership with Alvotech, which is Biosimilar pharmaceutical company to strengthen their business for developing Biosimilar drugs.

Sandoz and Just – Evotech Biologics decided to collaborate through a partnership to develop various Biosimilar drugs. This partnership also as resulted into former’s pipeline’s expansion to more than 20 biosimilar drugs.

Merck Bioventures and Hanwha made a partnership which involved approximately USD 7 Tn. to make a Biosimilar version of Enbrel which is a generic drug primarily used to treat Rheumatoid Arthritis and is currently developed by Pfizer and Amgen.

CONCLUSION

The United States Biosimilar Market can be best described as a market that is associated with the development of Biosimilar drugs which are an exact copy of original or generic drugs. There are various factors responsible for the growth of US Biosimilar Market.

Some of the major factors contributing to the growth of this market includes the cost-effective nature of Biosimilar drugs, rising geriatric population, rising cases of chronic diseases and increasing partnerships between companies to develop Biosimilar drugs.

[poonamcmi]

Global Targeted Drug Delivery Market Is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Delivery Systems

The global targeted drug delivery market is estimated to be valued at US$6,960 million in 2022 and is expected to exhibit a CAGR of 15.9% over the forecast period, according to a new report published by Coherent Market Insights. Market Overview: Targeted drug delivery refers to a method of delivering medication to specific tissues or cells in the body, minimizing the exposure of healthy tissues to the drug. This approach offers several advantages such as increased efficacy, reduced side effects, and improved patient compliance. The need for targeted drug delivery systems has emerged due to the limitations of traditional drug delivery methods. Market Key Trends: One key trend in the targeted drug delivery market is the increasing adoption of nanotechnology-based drug delivery systems. Nanoparticles enable precise targeting and controlled release of drugs, improving therapeutic outcomes. For example, Abbott Laboratories' Humira Pen for rheumatoid arthritis uses nanotechnology to deliver the drug directly to affected joints, reducing systemic exposure and adverse effects. PEST Analysis: - Political: Regulations and government policies play a crucial role in drug development and approval processes. Stringent regulations ensure the safety and efficacy of targeted drug delivery systems. - Economic: The growing prevalence of chronic diseases and the rising demand for personalized medicine drive the market's growth. Additionally, technological advancements and investments in research and development contribute to market expansion. - Social: Increasing awareness among patients about targeted drug delivery systems and the benefits they offer augments market demand. Moreover, the aging population, which is more susceptible to chronic diseases, also drives market growth. - Technological: Advances in drug delivery technologies such as nanotechnology, microencapsulation, and conjugation techniques have revolutionized targeted drug delivery. These technologies allow precise control over drug release, enhancing therapeutic efficacy. Key Takeaways: - The global Targeted Drug Delivery Market Growth is expected to witness high growth, exhibiting a CAGR of 15.9% over the forecast period, due to increasing demand for enhanced delivery systems. - Regionally, North America is the fastest-growing and dominating region in the market. This can be attributed to factors such as a well-established healthcare infrastructure, high healthcare expenditure, and technological advancements in drug delivery systems. - Key players operating in the global targeted drug delivery market include AbbVie Inc., Ablynx NV by Sanofi SA, Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca PLC, Boston Scientific Corporation, Becton, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC., Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd., and 3M Company. In conclusion, the global targeted drug delivery market is poised for rapid growth fueled by the increasing demand for enhanced drug delivery systems. The adoption of nanotechnology-based drug delivery systems and favorable government policies are further driving market expansion. North America is expected to emerge as the dominant region in the market due to a well-established healthcare infrastructure and technological advancements. Key players in the market are continuously investing in research and development to develop innovative targeted drug delivery solutions.

[poojascmi]

Global Biosimilars Market Is Estimated To Witness High Growth Owing To Increasing Demand for Cost-effective Treatment Options

The global Biosimilars market is estimated to be valued at USD 29.4 billion in 2023 and is expected to exhibit a CAGR of 17.8% over the forecast period of 2023-2028, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

Biosimilars are highly similar versions of approved biological medicines, also known as reference or originator products. These biologics are designed to have similar efficacy, safety, and quality as the reference product. They offer a cost-effective alternative to expensive biologic drugs, making them more accessible to patients globally. Biosimilars have gained significant traction in recent years due to their potential to reduce healthcare costs and increase patient access to life-saving treatments.

B) Market Dynamics:

The biosimilars market is driven by two key factors:

1. Cost-Effectiveness: Biosimilars are priced lower than their reference products, making them an attractive option for healthcare providers and patients. As healthcare costs continue to rise, the demand for affordable treatment options is increasing. Biosimilars provide a cost-effective alternative, allowing patients to access life-saving treatments without burdening their finances.

2. Patent Expiry of Biologic Drugs: Many biologic drugs have reached or are nearing their patent expiration, creating opportunities for biosimilar manufacturers. Patent expiry allows biosimilar manufacturers to enter the market and offer more affordable versions of popular biologic drugs.

For example, Novartis AG, one of the key players in the Biosimilars Market, has several biosimilar products in its pipeline, including biosimilar versions of adalimumab (Humira) and bevacizumab (Avastin). These biosimilars aim to provide cost-effective alternatives to patients suffering from chronic conditions like rheumatoid arthritis and cancer.

C) Market Key Trends:

One key trend in the biosimilars market is the increasing adoption of biosimilars in emerging markets. Emerging economies such as India, China, and Brazil are investing in the development and production of biosimilars to reduce healthcare costs and improve patient access to essential medicines. For example, Biocon Limited, an Indian biopharmaceutical company, has successfully launched several biosimilar products in emerging markets, including trastuzumab, rituximab, and insulin glargine.

D) SWOT Analysis:

Strengths:

1. Cost-Effectiveness: Biosimilars offer a more affordable alternative to expensive biologic drugs.

2. Increasing Demand: The rising prevalence of chronic diseases and the need for cost-effective treatment options drive the demand for biosimilars.

Weaknesses:

1. Regulatory Hurdles: The regulatory process for biosimilars is complex and time-consuming.

2. Limited Physician Adoption: Physicians may be hesitant to switch from originator biologics to biosimilars due to concerns about efficacy and safety.

Opportunities:

1. Patent Expiry: The expiry of patents for biologic drugs presents opportunities for biosimilar manufacturers to enter the market.

2. Emerging Markets: The growing demand for affordable treatment options in emerging markets provides a significant growth opportunity for biosimilar manufacturers.

Threats:

1. Brand Loyalty: Patients and physicians may have a strong preference for originator biologics, limiting the adoption of biosimilars.

2. Intellectual Property Rights: Risks associated with intellectual property infringement may hamper the growth of the biosimilars market.

E) Key Takeaways:

- The global biosimilars market is expected to witness high growth, exhibiting a CAGR of 17.8% over the forecast period, due to the increasing demand for cost-effective treatment options.

- The Asia Pacific region is expected to be the fastest growing and dominating region in the biosimilars market due to high demand, favorable government policies, and availability of skilled labor.

- Key players operating in the global biosimilars market include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, and Amgen, Inc.

[technewspoint]

HUMIRA (Adalimumab Drug) Market Size, Share, Industry Report, Growth, Analysis, Price, Trends, Outlook, Key Players and Forecast 2023-2031

http://dlvr.it/Ss2tR0